Strategic Financial Concepts LLC Takes $4.03 Million Position in GSK plc (NYSE:GSK)

Strategic Financial Concepts LLC acquired a new stake in GSK plc (NYSE:GSK) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 119,236 shares of the pharmaceutical company’s stock, valued at approximately $4,033,000.

Several other hedge funds have also recently added to or reduced their stakes in the stock. SG Americas Securities LLC raised its position in shares of GSK by 167.3% in the 3rd quarter. SG Americas Securities LLC now owns 18,773 shares of the pharmaceutical company’s stock valued at $767,000 after acquiring an additional 11,749 shares during the period. Brookstone Capital Management raised its holdings in GSK by 2.8% during the 3rd quarter. Brookstone Capital Management now owns 26,457 shares of the pharmaceutical company’s stock worth $1,082,000 after buying an additional 718 shares during the period. Ritholtz Wealth Management lifted its stake in GSK by 2.8% in the third quarter. Ritholtz Wealth Management now owns 78,540 shares of the pharmaceutical company’s stock valued at $3,211,000 after buying an additional 2,143 shares in the last quarter. Gilman Hill Asset Management LLC boosted its holdings in shares of GSK by 9.7% in the third quarter. Gilman Hill Asset Management LLC now owns 67,422 shares of the pharmaceutical company’s stock valued at $2,756,000 after buying an additional 5,965 shares during the period. Finally, Thomasville National Bank increased its position in shares of GSK by 2.5% during the third quarter. Thomasville National Bank now owns 475,384 shares of the pharmaceutical company’s stock worth $19,434,000 after acquiring an additional 11,771 shares in the last quarter. Institutional investors and hedge funds own 15.74% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on GSK. Guggenheim cut shares of GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. StockNews.com raised GSK from a “buy” rating to a “strong-buy” rating in a research report on Friday. Deutsche Bank Aktiengesellschaft lowered GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Finally, Jefferies Financial Group downgraded GSK from a “buy” rating to a “hold” rating and reduced their price target for the stock from $53.00 to $39.50 in a research report on Tuesday, November 12th. Six research analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the stock. According to MarketBeat.com, GSK currently has an average rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Stock Performance

Shares of NYSE GSK opened at $36.03 on Monday. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.53 and a current ratio of 0.78. The stock has a 50 day moving average price of $34.25 and a 200 day moving average price of $37.56. The stock has a market capitalization of $74.68 billion, a PE ratio of 22.66, a price-to-earnings-growth ratio of 1.42 and a beta of 0.64. GSK plc has a 52 week low of $31.72 and a 52 week high of $45.92.

GSK (NYSE:GSK) last released its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. Analysts predict that GSK plc will post 4.07 earnings per share for the current fiscal year.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be paid a dividend of $0.3932 per share. The ex-dividend date is Friday, February 21st. This is a positive change from GSK’s previous quarterly dividend of $0.39. This represents a $1.57 annualized dividend and a dividend yield of 4.36%. GSK’s payout ratio is currently 93.08%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.